No Data
Express News | EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $33
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $22
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
No Data
No Data
